Sanofi

🇫🇷France

Country: 🇫🇷France

Ownership: Public

Employees: 87.9K

Market Cap: $141.3B

Website: http://www.sanofi.com

Introduction: Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the following business segments: Pharmaceuticals, Consumer Healthcare, and Vaccines. The Pharmaceuticals segment comprises the commercial operations of the following global franchises: specialty care, diabetes and cardiovascular, established prescription products and generics, and research, development, and production activities. The Consumer Healthcare segment includes the commercial operations for its Consumer Healthcare products. The Vaccines segment consists commercial operations of Sanofi Pasteur. The company was founded in 1973 and is headquartered in Paris, France.

Clinical Trials

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: liraglutide
Drug: Insulin glargine/lixisenatide fixed ratio combination
Drug: exenatide
Drug: exenatide extended-release
Drug: albiglutide
Drug: dulaglutide

First Posted Date: 2016-06-01

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 514

Registration Number: NCT02787551

Locations: 🇺🇸
Investigational Site Number 8400033, Baltimore, Maryland, United States
🇺🇸
Investigational Site Number 8400079, Albany, New York, United States
🇺🇸
Investigational Site Number 8400019, Columbus, Ohio, United States

and more 121 locations

An Open-label, Ascending, Repeated Dose-finding Study of Sarilumab in Children and Adolescents With Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA)

Phase 2

Completed

Conditions: Juvenile Idiopathic Arthritis

Interventions: Drug: Sarilumab

First Posted Date: 2016-05-18

Last Posted Date: 2024-10-11

Lead Sponsor: Sanofi

Target Recruit Count: 102

Registration Number: NCT02776735

Locations: 🇨🇦
Investigational Site Number : 1240112, Montréal, Quebec, Canada
🇨🇱
Investigational Site Number : 1520016, Concepcion, Biobío, Chile
🇫🇷
Investigational Site Number : 2500040, Paris, France

and more 27 locations

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Insulin Glargine Alone on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine/lixisenatide (HOE901/AVE0010)
Drug: Insulin glargine (HOE901)
Drug: Oral anti-diabetic drugs

First Posted Date: 2016-04-27

Last Posted Date: 2020-06-16

Lead Sponsor: Sanofi

Target Recruit Count: 521

Registration Number: NCT02752828

Locations: 🇯🇵
Investigational Site Number 392024, Chiba-Shi, Japan
🇯🇵
Investigational Site Number 392025, Atsugi-Shi, Japan
🇯🇵
Investigational Site Number 392008, Fujimi-Shi, Japan

and more 110 locations

Efficacy and Safety of LixiLan Versus Insulin Glargine Alone Both With Metformin in Japanese With Type 2 Diabetes Mellitus Inadequately Controlled on Basal Insulin and Oral Antidiabetic Drugs

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Insulin glargine U100 (HOE901)
Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Drug: Metformin

First Posted Date: 2016-04-27

Last Posted Date: 2020-06-16

Lead Sponsor: Sanofi

Target Recruit Count: 513

Registration Number: NCT02752412

Locations: 🇯🇵
Investigational Site Number 392013, Chiyoda-Ku, Japan
🇯🇵
Investigational Site Number 392142, Kawasaki-Shi, Japan
🇯🇵
Investigational Site Number 392132, Annaka-Shi, Japan

and more 119 locations

Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (LixiLan) to Lixisenatide on Top of Oral Anti-diabetic Drugs (OADs) With Type 2 Diabetes in Japan

Phase 3

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Lixisenatide (AVE0010)
Drug: Insulin glargine/Lixisenatide (HOE901/AVE0010)
Drug: Oral anti-diabetic drugs

First Posted Date: 2016-04-25

Last Posted Date: 2020-06-16

Lead Sponsor: Sanofi

Target Recruit Count: 321

Registration Number: NCT02749890

Locations: 🇯🇵
Investigational Site Number 392068, Kitakyusyu-Shi, Japan
🇯🇵
Investigational Site Number 392044, Koga-Shi, Japan
🇯🇵
Investigational Site Number 392002, Adachi-Ku, Japan

and more 58 locations

Efficacy and Safety of Toujeo® Versus Tresiba® in Insulin-Naive Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Oral Antihyperglycemic Drug(s) ± GLP-1 Receptor Agonist

Phase 4

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Insulin glargine, 300U/mL
Drug: Insulin degludec, 100 U/mL
Drug: Non-insulin anti-diabetic treatment

First Posted Date: 2016-04-14

Last Posted Date: 2018-09-14

Lead Sponsor: Sanofi

Target Recruit Count: 929

Registration Number: NCT02738151

Locations: 🇺🇸
Investigational Site Number 840075, Bradenton, Florida, United States
🇺🇸
Investigational Site Number 840007, Dallas, Texas, United States
🇺🇸
Investigational Site Number 840036, Arlington Heights, Illinois, United States

and more 155 locations

Comparison of the Safety and Efficacy of HOE901-U300 With Lantus in Children and Adolescents With Type 1 Diabetes Mellitus

Phase 3

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: Insulin glargine (100 units /mL)
Drug: Insulin glargine,300 U/mL
Drug: Background therapy

First Posted Date: 2016-04-12

Last Posted Date: 2022-03-25

Lead Sponsor: Sanofi

Target Recruit Count: 463

Registration Number: NCT02735044

Locations: 🇧🇬
Investigational Site Number 1000005, Sofia, Bulgaria
🇨🇱
Investigational Site Number 1520004, Santiago, Chile
🇨🇿
Investigational Site Number 2030005, Ostrava - Poruba, Czechia

and more 104 locations

Evaluation of Alirocumab Versus Ezetimibe on Top of Statin in Asia in High Cardiovascular Risk Patients With Hypercholesterolemia

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: Placebo for alirocumab
Drug: Alirocumab
Drug: placebo for ezetimibe
Drug: ezetimibe
Drug: atorvastatin
Drug: rosuvastatin
Drug: simvastatin

First Posted Date: 2016-03-22

Last Posted Date: 2019-09-30

Lead Sponsor: Sanofi

Target Recruit Count: 615

Registration Number: NCT02715726

Locations: 🇨🇳
Investigational Site Number 1560018, Beijing, China
🇨🇳
Investigational Site Number 1560008, Hangzhou, China
🇨🇳
Investigational Site Number 1560009, Shenyang, China

and more 59 locations

Postprandial Glucodynamic Response to Insulin Glargine/Lixisenatide Fixed Ratio Combination in Japanese Patients With Type 2 Diabetes Mellitus

Phase 1

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Placebo
Drug: Insulin glargine HOE901
Drug: Insulin glargine/ lixisenatide fixed-ratio combination HOE901/AVE0010

First Posted Date: 2016-03-18

Last Posted Date: 2020-06-16

Lead Sponsor: Sanofi

Target Recruit Count: 20

Registration Number: NCT02713477

Locations: 🇯🇵
Investigational Site Number 392001, Fukuoka-Shi, Japan

A Study Comparing the Efficacy and Safety of the Morning Injection of Toujeo Versus Lantus in Patients With Type 1 Diabetes Mellitus

Phase 4

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Drug: HOE901-U300 (Insulin Glargine 300 U/ml)
Drug: Lantus (Insulin Glargine 100 U/ml)
Drug: Mandated back ground therapy

First Posted Date: 2016-02-23

Last Posted Date: 2022-03-28

Lead Sponsor: Sanofi

Target Recruit Count: 638

Registration Number: NCT02688933

Locations: 🇺🇸
Investigational Site Number 840-044, Los Angeles, California, United States
🇺🇸
Investigational Site Number 840-040, Henderson, Nevada, United States
🇺🇸
Investigational Site Number 840-019, Dallas, Texas, United States

and more 97 locations

Home Terms & Conditions Privacy Policy